

County Durham & Tees Valley Area Prescribing Committee

County Durham and Tees Valley Paediatric Asthma Inhaler Guide (for patients under 18 years)

The Pharmacological Management of Stable Asthma for Children

Version number	4.1 March 2022
Date of County Durham and Tees Valley APC approval:	March 2022
Date of review:	May 2023



Summary of the pharmacological management of asthma in children – under 18yrs (BTS, 2019)

From SIGN/BTS British guideline on the management of asthma, July 2019



Summary of the pharmacological management of asthma in adults (BTS. 2019)

From <u>SIGN/BTS British guideline on the management of asthma, July 2019</u>

The Pharmacological Management of Stable Asthma for Children under 18 years in Primary Care

Inhalers should always be prescribed by brand to prevent unintentional substitution and ensure patients receive a device they are familiar with. Inhalers are not in preference order, use right device for patient. All MDI devices should be used with a spacer V = Volumatic, A = Aerochamber plus compatible 1. Regular Preventer 2. Initial add-on Preventer 5 3. Additional add-on therapy Δ 2 years and over - very low dose ICS Under 5yrs - increase to low dose ICS 400mcg years and over - add LABALess High (if ICS not tolerated then Montelukast for under than 5 years - add LTRA daily(as per BTS) and refer Dose Over 5yrs - use low dose + LABA 5years) OR Add LTRA (appropriate for both) Therapies 2 - 11 years step 4 is increasing doses to high doses (refer to BNF), however if escalation to high dose needed referral to secondary care is required (child 2 – 11 years 2 – 11 years ICS ICS/ LABA ICS (<5yrs); ICS/LABA (>5yrs) 100 – 200mcg BDP equivalent/ day 100 – 200mcg BDP equivalent/ day 300 – 500mcg BDP equivalent/ day Symbicort (DPI) 100/6mcg Pulmicort Turbohaler (DPI) Symbicort (DPI) 100mcg 100/6mcg 2p BD 1p BD 1p BD (6 years +) nay need to be prescribed high dose whilst waiting for appointment – contact specialist if dose uncertain) (6 years+) Low Carbon (6 years+) ✓ Low Carbor Low Carbon Seretide Evohaler (MDI) ^v Clenil (MDI) ^v50mcg *if unable to use Symbicort move across to the 50/25mcg 2p BD next column 2p BD (2 years+) (4 years+) LTRA LTRA < 5 years (if ICS not tolerated) LTRA (add if under 5) Montelukast 4mg at night Montelukast 4mg at night(6 Montelukast 4mg at night(6 months – 5 years) (6 months – 5 years) months – 5 years) 5mg at night (6 – 14 years) 12 – 17 years 12 – 17 years 12 – 17 years ICS/LABA ICS/LABA ICS 400 – 500mcg BDP equivalent/ day 400 – 500mcg BDP equivalent/ day 800 – 1000mcg BDP equivalent/ day Pulmicort (DPI) 200 Turbohaler Symbicort (DPI) Symbicort (DPI) 1p BD 200/6mcg 200/6mcg 1p BD Fixed dose or 2p BD Fixed dose or (12 years+) Low Carbon SMART SMART (12 years+) (12 years+) 🗸 Low Carbon Low Carbon DuoResp Spiromax DuoResp Spiromax (DPI) 160/4.5 DPI) 160/4.5 1p BD Fixed dose or 2p BD Fixed dose or MART (12 years +) MART (12 years +) Low Carbon 🗸 Low Carbor Clenil (MDI)^v Seretide Evohaler Seretide Evohaler (MDI) v 100mcg (MDI) 125/25mcg 50/25mcg 2p BD 2p BD 2p BD (2 years+) 4 years+) (12 years+) Qvar Easibreathe (MDI)50mcg Relvar Ellipta (DPI) 92/22mcg 1p OD 2p BD (12 years +) ✓ Low Carbon <u>Or</u> 100mcg 1p BD (12 years+) Carbon Footprint. Only low carbon LTRA inhalersare annotated. Further Montelukast information on all inhalers and the 5mg at night (6 – 14 years) importance of returning allinhalers to the 10mg at night (14 years+) pharmacy for disposal in an environmentally safe way is available on https://greeninhaler.org/ RELIEVER THERAPY Bricanyl Turbohaler Salamol Easi-Breathe Ventolin Accuhaler Salamol (MDI) (DPI)200mcg (DPI)500mcg 100mcg (BAAI) 100mcg 1p PRN 1-2p PRN 1p PRN 1-2p PRN ^{V/A} (5 years+) (5 years+) 0 months+) (4 years+) 🗸 Low Carbor 🗸 Low Carbon Abbreviations

ICS = inhaled corticosteroid DPI = dry powder inhaler

LABA = long-acting beta agonist BAAI = breath-actuated aerosol inhaler BDP = beclomethasone dipropionate LTRA = leukotriene receptor antagonist MDI = metered dose inhaler LAMA = long-acting anti-muscarinic antagonist

County Durham and Tees Valley Paediatric Asthma Inhaler Guide (for patients<18 years)

Diagnosis – refer to BTS 2019 guidelines

Please ensure every patient with asthma receives a written, personalised action plan

Further information is available from the beat asthma website

Assess asthma control

- Use age appropriate Children's Asthma Control Test Age 4-11yrs or > 12 years
- RCP-3 questions are a QoF requirement, please ensure these are completed as part of annual review

Does the patient have any asthma triggers? See <u>Asthma UK website</u> for more information.

Any symptoms of rhinitis? If so, treat accordingly.

Review current treatment regime (consider video consultation)

Observe inhaler technique (placebo inhalers are available). Animated demonstrations for most inhaler devices can be viewed on the RightBreathe website.

Check adherence and concordance with patient:

- Does the patient/parent/carer understand when and why to use their inhalers?
- Is the patient using their inhalers as prescribed?
- Ordering >6 reliever inhalers per year may indicate poor control.
- Consider a telephone review if a face-to-face consultation is

not possible Check that the number of preventers issued corresponds

with the patient's prescribed regime, taking into account • the number of doses in the device. •

 ALWAYS ENSURE SPACER IS USED WITH ANY MDI DEVICE

If all points above are satisfactory, continue to the next step.

Stepwise management of asthma

Start at the step most appropriate to initial severity; before initiating a new drug or increasing the dose of an inhaler consider whether diagnosis is correct, check adherence to the treatment plan and inhaler technique, and eliminate trigger factors for acute exacerbations.

Step up if not controlled. If **complete control**, consider step down after 3 months in line with ACT score and clinical judgement.

Consider the patient's age, level of dexterity and lifestyle factors when selecting a suitable inhaler device. Animated demonstrations for most inhaler devices can be viewed on the Asthma UK website. See overleaf for inhaler choices for each step.

When to consider stepping up

Step up if any of the following features:

- Using SABA three times a week or more
- Symptomatic three times a week or more
- Waking one night a week
- Also consider in patients who have had asthma attack requiring corticosteroids in the last two years

Consider using ACT score as a tool in order to consider when to step up in therapy, but <u>also</u> when to consider stepping down (i.e. excellent control, demonstrated in high ACT score with clinical stability over several months-use inhaler guide to assist with this). Where a DPI is licensed but the patient is unable to use it effectively, please use the most appropriate MDI with a spacer.

Steroid cards

Steroid cards are recommended for patients taking doses of inhaled corticosteroids ≥800 micrograms BDP equivalent per day.

All patients taking oral steroids AND inhaled corticosteroids must be provided with a steroid card.

Self-Management and Action plans

A patient is four times less likely to require admission to hospital for their Asthma if they have a Personal Asthma Action Plan (PAAP).

If child is in Primary school, please consider giving <u>School Asthma</u> <u>Card</u>' available from Asthma UK:

Please use a valid PAAP for patients and code it's use on the clinical system. Use a code of declined or not appropriate where relevant. <u>Asthma UK</u> and the <u>beat asthma website</u> has plans, which are free to download and print (suggest that patients/parents/carers take a photo of their Asthma plan on their smartphone for ease of access and encourage to share with family members).

SMART[®] - maintenance and reliever therapy regime

Symbicort[®] (100/6) can be used for both maintenance and relief medication instead of a separate SABA for patients who have seen a benefit with a LABA but are still not controlled at step 3. (AGE 12+ ONLY)

SMART[®] can be considered for patients with:

Inadequate asthma control and a frequent need for reliever medication

Asthma exacerbations in the past requiring medical intervention A good understanding of asthma and symptoms

Patients must have received education on the use of the inhaler as maintenance and reliever therapy and clinicians must be confident patients understand how to use it appropriately.

Patients should be advised to always have their inhaler available for reliever use. Patients requiring frequent use of rescue inhalations

should be advised to return to the GP practice for reassessment. Practices should monitor the number of prescriptions requested and any dose-related side-effects. Patients using more than one extra relief puff on a regular basis should be reviewed and their maintenance therapy should be reconsidered.

Patients must be encouraged to take part in the national flu campaign

<u>For use in emergency situations only</u> all patients should have a salbutamol inhaler and a large volume spacer. Please discuss with a respiratory specialist if uncertain.

Important – Non attendance

When a child aged 16 years or under is not brought to clinic for review, a code of **'child not brought to appointment'** should be used within the patient notes:

Attempts should be made to contact the parent/carer to question why missed appointment. f contact with parent/carer not possible/fails, consider safeguarding.

Waste and Recycling - Used pMDI canisters still contain propellants; all used pMDI canisters should be returned to a pharmacy (or dispensing GP practice) to dispose of in an environmentally safe way

Childhood Asthma Control Test for children 4 to 11 years old.

Know the score.

This test will provide a score that may help your doctor determine if your child's asthma treatment plan is working or if it might be time for a change.

How to take the Childhood Asthma Control Test

- Step 1 Let your child respond to the first four questions (1 to 4). If your child needs help reading or understanding the question, you may help, but let your child select the response. Complete the remaining three questions (5 to 7) on your own and without letting your child's response influence your answers. There are no right or wrong answers.
- Step 2 Write the number of each answer in the score box provided.
- Step 3 Add up each score box for the total.
- Step 4 Take the test to the doctor to talk about your child's total score.

Have your child complete these questions.

1. How is your asthma today?







Bad





Good



If your child's score is 19 or less, it may be a sign that your child's asthma is not controlled as well as it could be. No matter what the score, bring this test to your doctor to talk about your child's results.

SCORE



Very bad

2. How much of a problem is your asthma when you run, exercise or play sports?





It's abig problem, I can'tdo what I want todo. It's aproblem and I don'tlike it. It's a little problem but it's okay.

3. Do you cough because of your asthma?



Yes, all of the time.



Yes, most of the time.







Yes, some of the time.







Yes, all of the time. Yes, most of the time. No, none of the time. Yes, some of the time. Please complete the following questions on your own. 5. During the last 4 weeks, on average, how many days per month did your child have any daytime asthma symptoms? 0 5 11-18 days/mo Not at all 1-3 davs/mo 4-10 days/mo 19-24 days/mo Everyday 6. During the last 4 weeks, on average, how many days per month did your child wheeze during the day because of asthma? 0 Not at all 4-10 days/mo Everyday 1-3 days/mo 11-18 days/mo 19-24 days/mo 7. During the last 4 weeks, on average, how many days per month did your child wake up during the night because of asthma? Not at all 1-3 days/mo 4-10 days/mo 11-18 days/mo 19-24 days/mo Everyday Please turn this page over to see what your child's total score means.













No, none of the time.



It's not a problem.





What does it mean if my child scores 19 or less?

- If your child's score is 19 or less, it may be a sign that your child's asthma is not under control.
- Make an appointment to discuss your child's asthma score with their doctor. Ask if you should change your child's asthma treatment plan.
- Ask your child's doctor about daily long-term medications that can help control airway inflammation and constriction, the two main causes of asthma symptoms. Many children may need to treat both of these on a daily basis for the best asthma control.

Asthma Control Test for Children aged 12 years and over

Asthma UK is the only charity dedicated to the health and well-being of the 5.2 million
people in the UK with asthma. By taking control of their asthma, most people's day-to-
day lives should be free from disruption such as troubled sleep or not being able to
exercise.

Asthma Control Test[™]



Why take the Asthma Control Test™?

The Asthma Control Test[™] will provide you with a snapshot of how well your asthma has been controlled over the last four weeks, giving you a simple score out of 25. Asthma symptoms can vary from month to month, so it is worth keeping the test handy to see if your score changes. You can also share your results with your doctor or asthma nurse to help explain just how your asthma affects you.



What does your score mean?

- Score:25-WELLDONE
- Your asthma appears to have been UNDER CONTROL over the last 4 weeks.
- However, if you are experiencing any problems with your asthma, you should see your doctor or nurse.

Score: 20 to 24 - ON TARGET Your asthma appears to have been

- REASONABLY WELL CONTROLLED during the past 4 weeks. However, if you are experiencing
- symptoms your doctor or nurse may be able to help you.

What can you do now?

Like many other people in the UK, it is possible that your asthma could have less impact on your everyday life. You can get a free pack full of information about how to take control of your asthma, including an action plan to fill in with your doctor or asthma nurse, from Asthma UK

© 2002, by QualityMetric Incorporated. Asthma Control Test is a trademark of QualityMetric Incorporated. "US English version modified for use in UK". The production of this leaflet has been supported by GlaxoSmithKline

Registered charity number 802364

Score: less than 20–OFF TARGET

CONTROLLED during the past 4 weeks.

Your doctor or nurse can recommend

- Your asthma may NOT HAVE BEEN

an asthma action plan to help

improve your asthma control.

Management of acute asthma in children < 18yrs in general practice

Age 2–5 years			Age >5 years ASSESS AND RECORD ASTHMA SEVERITY				
ASSESS AND RECORD ASTHMA SEVERITY							
Moderate asthma • SpO ₂ ≥92% • Able to talk • Heart rate ≤140/min • Respiratory rate ≤40/min	Acute severe asthm • SpO ₃ <92% • Too breathless to • Heart rate >140/m • Respiratory rate > • Use of accessory m muscles	a talk nin 40/min teck	Life-threatening asthma SpO ₂ <92% plus any of: • Silent chest • Poor respiratory effort • Agitation • Confusion • Cyanosis	Moderate asthma • SpO ₂ ≥92% • Able to talk • Heart rate ≤125/min • Respiratory rate ≤30/min • PEF ≥50% best or predicted	Acute severe asthma • SpO ₂ <92% • Too breathless to t • Heart rate >125/m • Respiratory rate > • Use of accessory n muscles • PEF 33–50% best of	alk iin 30/min eck r predicted	Life-threatening asthma SpO ₂ <92% plus any of: • Silent chest • Poor respiratory effort • Agitation • Confusion • Cyanosis • PEF <33% best or predicted
						-	
 β₂ bronchodilator: via spacer ± facemask* Consider oral prednisolone 20 mg 	 Oxygen via facem β₂bronchodilator via nebuliser (pr oxygen-driven), salbutamol 2.5 n or, if nebuliser n via spacer* Oral prednisolone Assess response to 15 mins after β₂ bro 	ask to mainta eferably ng ot available, 20 mg treatment nchodilator	 ain SpO₂ 94–98% if available β₂ bronchodilator with ipratropium: via nebuliser (preferably oxygen-driven), salbutamol 2.5 mg and ipratropium 0.25 mg every 20 minutes or, if nebuliser and ipratropium not available, β₂ bronchodilator via spacer* Oral prednisolone 20 mg or IV hydrocortisone 50 mg if vomiting 	 β₂ bronchodilator: via spacer* Consider oral prednisolone 30–40 mg 	 Oxygen via facem β₂ bronchodilator via nebuliser (provide the system), 5 mg or, if nebuliser nevia spacer* Oral prednisolone 30–40 mg Assess response to 15 mins after β₂ bronce the system of th	ask to mainta eferably salbutamol ot available, treatment nchodilator	 spO₂ 94–98% if available β₂ bronchodilator with ipratropium: via nebuliser (preferably oxygen-driven), salbutamol 5 mg and ipratropium 0.25 mg every 20 minutes or, if nebuliser and ipratropium not available, β₂ bronchodilator via spacer* Oral prednisolone 30–40 mg or IV hydrocortisone 100 mg if vomiting
		-				-	
IF POOR RESPONSE ARRANGE ADMISSION	GE IF POOR RESPONSE REPEAT β ₂ BRONCHODILATOR AND ARRANGE ADMISSION		REPEAT β, BRONCHODILATOR VIA OXYGEN-DRIVEN NEBULISER WHILST ARRANGING IMMEDIATE HOSPITAL ADMISSION	IF POOR RESPONSE ARRANGE ADMISSION	IF POOR RESPONSE REPEAT β, BRONCHODILATOR AND ARRANGE ADMISSION		REPEAT β ₂ BRONCHODILATOR VIA OXYGEN-DRIVEN NEBULISER WHILST ARRANGING IMMEDIATE HOSPITAL ADMISSION
GOOD RESPONSE POOR RESPONSE • Continue β₂ bronchodilator via spacer or nebuliser, as needed but not exceeding 4 hourly • Stay with • Send writ • If symptoms are not controlled • Repeat £		ONSE n patient until ambulance arrives tten assessment and referral details bronchodilator via oxygen-driven	 GOOD RESPONSE Continue β₂ bronchodilator via s as needed but not exceeding 4 If symptoms are not controlled 	r via spacer or nebuliser, ing 4 hourly rolled repeat		OOR RESPONSE Stay with patient until ambulance arrives Send written assessment and referral details Repeat β ₃ bronchodilator via oxygen-driven nebuliser in ambulance	
 repeat β₂ bronchodilator and refer to hospital Continue prednisolone until recovery (minimum 3-5 days) Arrange follow-up clinic visit within 48 hours Consider referral to secondary care asthma clinic if 		nebuliser in ambulance		 β₂ bronchodilator and refer to hospital Continue prednisolone until recovery (minimum 3-5 days) Arrange follow-up clinic visit within 48 hours Consider referral to secondary care asthma clinic 			
LOWER THRESHOLD FOR ADMIS Attack in late afternoon or at n Recent hospital admission or p Concern over social circumstar	SION IF: ight previous severe attack nces or ability to cope a	it home	NB: If a patient has signs and symptoms across categories, always treat according to their most severe features	Concern over social circumstar	SION IF: ight revious severe attack nces or ability to cope a	t home	NB: If a patient has signs and symptoms across categories, always treat according to their most severe features

* \$ 3 pronchodilator via spacer given one puff at a time, inhaled separately using tidal breathing; according to response, give another puff every 60 seconds up to a maximum of 10 puffs

Manageme	ent of acute asthr	na in adults in gen	eral practice					
Manageme Many deaths from asthma are preventable fatal. Factors leading to poor outcome in Clinical staff failing to assess severity by measurement Patients or relatives failing to appreciat Under use of corticosteroids Regard each emergency asthma consultat severe asthma until shown otherwise. Moderate asthma	ent of acute asthr le. Delay can be clude: y objective te severity ion as for acute Acute se	Assess and record: Peak expiratory flow (PEF) Symptoms and response to self treatment Heart and respiratory rates Oxygen saturation (by pulse oximetry) Caution: Patients with severe or life-threatening attacks may not be distressed and may not have all the abnormalities listed below. The presence of any should alert the doctor. Vere asthma Life-threatening asthma						
PEF>50-75% best or predicted	PEF 33-50%	best or predicted	PEF<33% best or predicted					
	FURTHER	ASSESSMENT						
 SpO₂ ≥92% Speech normal Respiration <25 breaths/min Pulse <110 beats/min 	 SpO₃ ≥92% Can't complete sentences Respiration ≥25 breaths/min Pulse ≥110 beats/min 		 SpO₂ <92% Silent chest, cyanosis or poor respiratory effort Arrhythmia or hypotension Exhaustion, altered consciousness 					
	MANA	GEMENT						
Treat at home or in surgery and ASSESS RESPONSE TO TREATMENT	Conside	er admission	Arrange immediate ADMISSION					
	TREA	TMENT						
 β₂ bronchodilator: via spacer* If no improvement: via nebuliser (preferably oxygendriven), salbutamol 5 mg Give prednisolone 40–50 mg Continue or increase usual treatment If good response to first treatment (symptoms improved, respiration and pulse settling and PEF >50%) continue or increase usual treatment and continue prednisolone 	 Oxygen to maintain SpO₂ 94–98% if available β₂ bronchodilator: via nebuliser (preferably oxygendriven), salbutamol 5 mg or if nebuliser not available, via spacer* Prednisolone 40–50 mg or IV hydrocortisone 100 mg If no response in acute severe asthma: ADMIT 		 Oxygen to maintain SpO₂ 94–98% β₂ bronchodilator with ipratropium: via nebuliser (preferably oxygen-driven), salbutamol 5 mg and ipratropium 0.5mg or if nebuliser and ipratropium not available, β₂ bronchodilator via spacer* Prednisolone 40–50 mg or IV hydrocortisone 100 mg immediately 					
 Admit to hospital if any: Life-threatening features Features of acute severe asthma present after initial treatment Previous near-fatal asthma Lower threshold for admission if afternoon or evening attack, recent nocturnal symptoms or hospital admission, previous severe attacks, patient unable to assess own condition, or concern over social circumstances 	 If admitting the pat Stay with patie arrives Send written arreferral details β₂ bronchodila nebullser in am 	ient to hospital: nt until ambulance sssessment and to hospital tor via oxygen-driven bulance	 Follow up after treatment or discharge from hospital: Continue prednisolone until recovery (minimum 5 days) GP review within 2 working days Monitor symptoms and PEF Check inhaler technique Written asthma action plan Modify treatment according to guidelines for chronic persistent asthma Address potentially preventable contributors to admission 					

* β₂ bronchodilator via spacer given one puff at a time, inhaled separately using tidal breathing; according to response, give another puff every 60 seconds up to a maximum of 10 puffs
From CLON/DTC Dritich puideling on the grades are set of active public 2010.

From SIGN/BTS British guideline on the management of asthma, July 2019